Appendix C

Statement of Task

An ad hoc planning committee will plan and conduct a public workshop that will examine the impact of and investment in the use of genetic and genomic data in drug development. The workshop will feature presentations and discussions from an array of stakeholders which may include leaders from academia, industry, and governmental organizations. The goal of the workshop will be to discuss how genomic and genetic data has been and will be used in the drug development process to improve aspects such as target identification, clinical trial design, pharmacogenomics approaches, biomarker development, and understanding disease biology. The workshop will also investigate the economic drivers, incentives, and models that use genomics in drug development. The planning committee will develop the workshop agenda, select and invite speakers and discussants, and moderate the discussions. An individually authored summary of the workshop will be prepared by a designated rapporteur in accordance with institutional policy and procedures.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement



Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 81
Appendix C Statement of Task An ad hoc planning committee will plan and conduct a public work- shop that will examine the impact of and investment in the use of genetic and genomic data in drug development. The workshop will feature presen- tations and discussions from an array of stakeholders which may include leaders from academia, industry, and governmental organizations. The goal of the workshop will be to discuss how genomic and genetic data has been and will be used in the drug development process to improve aspects such as target identification, clinical trial design, pharmacogenomics approaches, biomarker development, and understanding disease biology. The workshop will also investigate the economic drivers, incentives, and models that use genomics in drug development. The planning committee will develop the workshop agenda, select and invite speakers and discussants, and moderate the discussions. An individually authored summary of the workshop will be prepared by a designated rapporteur in accordance with institutional policy and procedures. 81

OCR for page 81